Merz Pharmaceuticals

CompanyGermany

Merz Pharmaceuticals develops one asset, approved (memantine in Alzheimer's disease). Mostly small molecule acting on GRIN2B, GRIN1 and GRIN2A; based in Germany.

Assets
1
Furthest
Approved
Trials
3
Signals
0

Pipeline

1

  • memantine

    Uncompetitive NMDA receptor antagonist protecting against glutamate excitotoxicity

    ApprovedSmall moleculeGRIN2BGRIN1Alzheimer's diseasedementia

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms2
  • Trials5
  • Similar companies6

Updated 7 Oct 2026 · 39 sources

Intelligence